- An in depth discussion on the disputed inventorship surrounding an anti-PD-L1 antibody patent
- Exclusive insights on the relationship between the degree of contribution and inventorship
- A detailed exploration of Japanese patent law and its applications through a case study example
- Expert examination of the pivotal issues in the AI legal space, including how the contrasting judicial systems in the US, Europe and Asia present challenges to innovation
- In-depth discussion on the strategic decisions are required for companies when constructing claims.
- Exclusive insight into when companies should opt for the patent route and which innovations should be protected by developing trade secrets?
Your Title Here
We're delighted to work with some of the leading life sciences experts from around the world, and to be able to share their content with our members. Check here for regular updates and case studies on the industry's key challenges.
Case Study: Clinical trials for original drugs fall under experimental use exception
The breadth of experimental use exceptions for patent infringement is a hot topic in the worldwide life sciences. Recent developments in Japan have shed new light on this important area.
In 2019, the University of Tokyo verified a high therapeutic effect in investigator-initiated clinical trials of a virus therapy for brain tumours. It applied for manufacturing and selling approval of the first domestic cancer treatment viral drugs.
The ensuing case has clarified the rules around exceptions for experimental use in Japan, explains Takanori Abe of Abe & Partners in this new case study report from LSPN Connect.
In recent years, second medical use patents have been the subject of myriad litigations and there has been a selection of interesting results across many jurisdictions. LSPN Connect recently tackled this tricky and timely topic with Sheldon Hamilton, partner, Smart & Biggar; Shahan Islam, senior counsel for patents, Pfizer; John Liddicoat, senior research associate, University of Cambridge; Jackie Mulryne, partner, Arnold & Porter; and Justin Turner, QC, Three New Square Chambers, and has published a special report based on their discussion.
Antibody patents are one of the most highly disputed issues in the life sciences field. Access this special report, by Abe & Partners, for:
2020 was a year like no other for life sciences and IP practitioners. The COVID-19 pandemic, as well as the impact of the UK’s departure from the EU, have presented challenges, but also perhaps opportunities, for the life sciences and medical devices industries globally.
We’ve been discussing these issues in detail with some of the industry’s leading practitioners on LSPN Connect and have compiled their insights into a special report: LSPN Perspectives.
Special Report: Artificial intelligence and IP
While AI offers exciting and unprecedented opportunities for life sciences and healthcare, it also poses complex questions, including how best to protect innovations in AI and what is the legal status of innovations that are produced, or even invented, by AI processes.
Download this special report for:
On-demand sessions
Catch up on sessions you've missed to hear what our experts have to say on hot topics such as AI, Biologics, Covid-19, CRISPR and loads more. With an LSPN Connect membership, you can experience everything LSPN Connect has to offer from on-demand and live sessions, to the community lounge where you can message and network with your peers.